An interventional study of Lung Cancer Screening Invitation Intervention and Abdominal scan intervention in Renal Cell Carcinoma (Kidney Cancer), Kidney Cancers and AAA - Abdominal Aortic Aneurysm, sponsored by University of Cambridge. Recruiting at 1 site in United Kingdom. Open to participants aged 55 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-19.
Sponsored by University of Cambridge · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 168 studies in Carcinoma, Renal Cell with a site in United Kingdom — 13 open to participants now, 30 under way, 13 of them phase 3. Carcinoma, Renal Cell · United Kingdom.
Among the 168 studies in Carcinoma, Renal Cell with a site in United Kingdom, this one has the largest planned enrollment of the 148 interventional ones that give a count, is one of 3 that started in 2025, is one of 8 with no phase, reaches primary completion later than 21 of the 29 other live ones, and was the 164th registered.
2,038 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.
Browse Carcinoma, Renal Cell studies →13 of the 168 studies in Carcinoma, Renal Cell with a site in United Kingdom are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United Kingdom, United States, Argentina and 16 more countries
Ages 18+
Bristol-Myers Squibb · Sites in United Kingdom, United States, Argentina and 17 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in United Kingdom, United States, Argentina and 21 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in United Kingdom, United States, Chile and 5 more countries
Ages 18–120
MacroGenics · Sites in United Kingdom, United States, Australia
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.
This study: 55 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
168 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 69 · Phase 3 51
First in 1996; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 6,272 is above the median of 43 across 1,565 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 189 across the 148 interventional studies, 281 across the 15 observational. Of the 124 that completed or were terminated, 66 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
130 of 168 have an industry lead sponsor. The 10 most frequent:
University of Cambridge is the lead sponsor of 116 studies on the registry; 23 are open to participants now.
University of Cambridge has 1 study filed under Carcinoma, Renal Cell — fewer than ten, so there is no comparison to draw.
6 of the studies in Carcinoma, Renal Cell with a site in United Kingdom that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT05678673Phase 3ExelixisStudy of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | 2026-12-15 |
| NCT05176483ExelixisStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors | 2027-01-31 |
| NCT05433142Xencor, Inc.Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | 2027-02 |
| NCT02568267Hoffmann-La RocheBasket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 168 studies in Carcinoma, Renal Cell with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Early detection through screening can improve cancer survival by identifying it when it's most treatable. The NHS now offers Lung Cancer Screening (LCS) assessments to people aged 55-74 who have ever smoked. Those at higher risk of lung cancer are offered a lung scan.
This group also has a high risk of developing abdominal cancers, such as kidney cancer. A recent study explored whether it would be feasible to extend the lung scan to include the abdomen. Results showed most participants supported this addition, and the number of serious findings was similar to those detected in UK breast or bowel cancer screening programmes.
However, the abdominal scan was only offered on the day of the lung scan, giving little time for people to consider their decision. The process also added too much time to be practical for widespread implementation.
This new study will:
People aged 55-70 who are invited to the lung cancer screening will be eligible to take part in this study. Only those who are found to be at a high risk of lung cancer after their assessment, and therefore offered a lung scan, will be offered the abdominal scan, provided they have not had an abdominal scan in the previous 12 months or one booked in the next 3 months.
This study will take place in two existing lung cancer screening locations in Yorkshire.
For the individual level randomisation to invitation control or invitation intervention
Inclusion criteria: To be randomised at the individual level to receive an invitation letter for LCS (standard of care; invitation control) versus invitation letter for LCS with potential for an additional abdominal scan (invitation intervention):
Exclusion criteria
Eligibility criteria for the cluster level randomisation to scan intervention or scan control
Inclusion criteria a): To be eligible for the cluster level randomisation the participant must:
Inclusion criteria b): To receive the CT Thorax plus ANCCT, the participant must:
Exclusion criteria
Existing LCS exclusion criteria:
Additional TACTICAL1 exclusion criteria:
Participants: People individually randomised to the invitation intervention arm who attend the LCS assessment or the scanning unit within the study period and who agree to be interviewed.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Invited to NHS Lung Cancer Screening to assess lung cancer risk via letter or text message, following the normal process
Other: Lung Cancer Screening Invitation Intervention
Will have additional text included in the standard Lung Cancer Screening letter or text explaining that, if eligible, they may also be offered a scan of their abdomen at the same time as their lungs.
Other: Lung Cancer Screening Invitation Intervention
For the scan control batches, those who are 'high risk' following the LCS assessment will have an appointment booked for LCS in the normal way by the LCS assessor.
Diagnostic Test: Abdominal scan intervention
Those who are 'high risk' following the LCS assessment will be invited to have an abdominal CT scan at the same time as their lung scan.
Diagnostic Test: Abdominal scan intervention
Participants are invited to the NHS Lung Cancer Screening to assess lung cancer risk via letter or text message
Receiving an abdominal CT scan at the same time as the lung scan.
Attendance rate at the LCS phone call
Attendance rate of the invitation intervention group to the LCS phone call is non-inferior to the attendance rate of the invitation control group and if so, whether it is superior.
Time frame: 12 weeks after invitation letter is sent
Cluster randomisation assessment
Successful cluster randomisation of participants into scan control and scan intervention groups as demonstrated by groups of similar size.
Time frame: At the point of LCS assessment, within 12 weeks of invitation
Impact of abdominal scan on throughput
Average number of participants scanned per standard LCS scanning day is no different when adding the ANCCT
Time frame: Up to 6 months after invitation
Perceived impact of abdominal scan on throughput
Data from daily short questionnaire completed by scanning unit staff shows perceived impact of TACTICAL activities on normal LCS processes is no different when ANCCT is added for at least 80% of days
Time frame: Up to 6 months after invitation
Incremental time taken for each TACTICAL1 task compared with the existing LCS processes.
The observed incremental time taken for each TACTICAL1 task compared with the existing LCS processes for a sub-sample of participants.
Time frame: Up to 6 months after invitation
Over 75% of participants receiving abdominal scan are satisfied or very satisfied with their scanning unit experience
Over 75% of participants are satisfied or very satisfied with their scanning unit experience as demonstrated by a post-scan feedback questionnaire.
Time frame: Up to 6 months after invitation
Percentage of participants taking up offer of abdominal scan
At least 80% of participants offered the ANCCT, accept the invitation and attend the scan
Time frame: Up to 6 months after invitation.
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Oct 2027, 23 months after the start.
Of 119 non-industry interventional studies with no phase under Carcinoma, Renal Cell, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 114. This study's planned 23 months is below that.
Counting every sponsor, half of 126 studies reached it within 45 months; a quarter within 22 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.